Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease

Journal of Nuclear Medicine

Volumn 51, Issue 4, 2010, Pages 588-595

  Van Laere, Koen ^a   Clerinx, Kristien ^a   D'Hondt, Eduard ^a   De Groot, Tjibbe ^a   Vandenberghe, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

11C raclopride; Binding potential; Discriminant analysis; Multiple system atrophy; Parkinson disease; Tracer influx

Indexed keywords

DOPAMINE 2 RECEPTOR; RACLOPRIDE C 11; DIAGNOSTIC AGENT; RACLOPRIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; FOLLOW UP; HUMAN; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SHY DRAGER SYNDROME; BRAIN CIRCULATION; CASE CONTROL STUDY; DISCRIMINANT ANALYSIS; EARLY DIAGNOSIS; FEMALE; MALE; METABOLISM; MIDDLE AGED; NEOSTRIATUM; PATHOPHYSIOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

AGED; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEOSTRIATUM; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE;

EID: 77950954215     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.070144     Document Type: Article

References (31)

1. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol. 2004;3:93-103.
2. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163:94-98. (Pubitemid 29155424)
3. Osaki Y, Wenning GK, Daniel SE, et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology. 2002;59:1486-1491.
4. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol. 2008;7:417-424.
5. Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord. 2009;24:949-964.
6. 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184-192.
7. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997;120:2187-2195.
8. Nakagawa M, Kuwabara Y, Taniwaki T, et al. PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. Ann Nucl Med. 2005;19:267-275. (Pubitemid 41105126)
9. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73:517-523.
10. 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004;31:1128-1135.
11. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677-692.
12. 123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov Disord. 2004;19:1438-1445.
13. Schulz JB, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZMSPECT. J Neurol Neurosurg Psychiatry. 1994;57:1047-1056.
14. 123I-IBZM single photon emission computed tomography. Arch Neurol. 1993;50:513-516.
15. Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med. 1997;38:1711-1717.
16. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303-312.
17. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33-39.
18. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57:1497-1499. (Pubitemid 32995738)
19. Cumming P, Rosa-Neto P, Watanabe H, et al. Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage. 2003;19:1127-1136.
20. 2 receptor density measured by [123I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry. 2000;157:127-129.
21. Van Laere K, Nuttin B, Gabriels L, et al. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med. 2006;47:740-747. (Pubitemid 46768435)
22. Van Laere K, Casteels C, De CL, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47:384-392. (Pubitemid 46768479)
23. Eckert T, Tang C, Ma Y, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008;23:727-733.
24. Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy. Clin Auton Res. 2004;14:84-91.
25. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A. Subcortical elevation of metabolism in Parkinson's disease: a critical reappraisal in the context of global mean normalization. Neuroimage. 2009;47:1514-1521.
26. Borghammer P, Jonsdottir KY, Cumming P, et al. Normalization in PET group comparison studies: the importance of a valid reference region. Neuroimage. 2008;40:529-540.
27. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 2006;67:1612-1617.
28. 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging. 2003;30:16-24.
29. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-676.
30. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry. 2005;76:423-425.
31. Van Laere K, Varrone A, Booij J, et al. European Association of Nuclear Medicine guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, v2. Eur J Nucl Med Mol Imaging. 2010;37:434-442.